Novo Nordisk's AI Gambit Meets a Brutal Price War

Novo Nordisk partners with OpenAI to counter Eli Lilly's tech edge while slashing prices in a fierce weight-loss drug market battle, as new oral competitors emerge.

The battle for supremacy in the lucrative weight-loss drug market is escalating on two fronts. While Novo Nordisk races to close a technological gap with rival Eli Lilly through a landmark AI partnership, it is simultaneously being forced into an aggressive price-cutting duel for patient wallets. The Danish pharmaceutical giant's stock, down roughly 22% year-to-date to trade around €34.71, reflects the intense pressure from this two-pronged challenge.

Novo's strategic response to Lilly's technological moves came in the form of a sweeping collaboration with OpenAI, announced this week. The partnership aims to overhaul the company's operations—from drug discovery and manufacturing to sales—by the end of 2026. The immediate goal is to use artificial intelligence to analyze complex datasets and identify promising drug candidates faster than traditional methods. In tandem, OpenAI will begin training Novo's global workforce, with pilot projects in research launching immediately.

This AI offensive is a direct counter to Eli Lilly's own tech alliance with Insilico Medicine, secured in March. The urgency for Novo is palpable, especially after Lilly received US approval for its new weight-loss pill, Foundayo, on April 1, 2026. The arrival of this oral competitor has ignited a fierce pricing battle that is now a central focus for investors.

The price war unfolded rapidly. Eli Lilly initially set Foundayo's price at up to $399 per month. Novo countered by pricing its Wegovy tablet between $149 and $299. In response, Lilly retreated to a $299 price point, but only for patients who continuously renew their prescription. Meanwhile, Novo's own introductory offer for the 4mg Wegovy tablet expired on April 15, causing its price to rise from $149 to $199 monthly, with higher maintenance doses costing $299. Looking ahead, Novo has already signaled a drastic list price cut for 2027, planning to slash costs for its three main products to around $675 monthly—a move that would roughly halve current prices.

Beyond price, Novo is leveraging clinical data to defend its position. At a recent medical conference, the company presented its ORION study, which showed its Wegovy tablet achieved a 13.6% weight reduction over 64 weeks, outperforming Lilly's orforglipron (11.2% over 72 weeks). A separate analysis found 84% of patients preferred a drug profile similar to Novo's semaglutid. The company also touts the long-term safety record of its injectable semaglutid. However, its oral product carries a practical disadvantage: it must be taken in the morning at least 30 minutes before eating, a restriction Lilly's pill does not have.

To lock in patients early, Novo has introduced a subscription model. Patients who commit to three, six, or twelve months pay less, saving up to $1,200 annually on injections and up to $600 on pills. This strategy targets a key demographic: the majority of current Wegovy patients are new to GLP-1 therapies altogether.

Financially, the headwinds are clear. While Novo Nordisk delivered a robust $43 billion in revenue for 2025, management now forecasts a single- to low-double-digit percentage decline in both sales and operating profit for the current year. The new AI initiative is therefore also tasked with driving down costs swiftly. Company CEO Mike Doustdar emphasized that the technology is meant to accelerate human decision-making, not replace it, with both firms establishing strict data control frameworks.

The stock's steep decline has pushed its Relative Strength Index (RSI) to a deeply oversold level of 25. Trading more than 50% below its 52-week high, the share price underscores investor concern. The coming weeks will serve as a critical gauge for how quickly Foundayo captures prescriptions. For Novo Nordisk, the race is on to prove its dual strategy of AI-powered innovation and aggressive commercial tactics can reclaim lost ground and reverse the market's pessimistic sentiment.